-
PROVIDERS
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
LIFE SCIENCES
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
09/20/2022
Patient recruitment at the speed of science
Learn how Sermonix Pharmaceuticals partnered with Tempus and its TIME network of clinical sites to accelerate patient recruitment for a phase 2 study.
Authors
Sibel Blau, MD
President and CEO, Quality Cancer Care Alliance Network
Medical Director, Northwest Medical Specialties
Matthew Cooney, MD
Vice President, Therapeutic Development, Tempus
President and CEO, Quality Cancer Care Alliance Network
Medical Director, Northwest Medical Specialties
Matthew Cooney, MD
Vice President, Therapeutic Development, Tempus
-
11/21/2024Precision outcomes research: Shaping the future of oncology biopharma with real-world evidence
Delve into the evolving landscape of outcomes research with a focus on real-world evidence (RWE) and advanced analytics.
Watch replay -
11/21/2024An algorithmic approach to close care gaps for patients that may benefit from confirmatory IHC HER2 testing
In partnership with a global pharmaceutical company, Tempus Next deployed a HER2 predictive algorithm at selected sites within the Tempus network. This algorithm was used during routine xR (whole transcriptome RNA) tests to identify patients who may benefit from additional confirmatory IHC HER2 testing.
Read more -
11/13/2024Navigating complex cell therapy trials with Compass CRO
Learn how Compass provided CRO services for a biotech’s first-in-human, dose-escalation, and expansion basket trial targeting advanced solid tumors.
Read more